UNSPSC 51392803: Prinoxodan

This classification denotes a phosphodiesterase inhibitor with the molecular formula C13H14N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W4VMH2E80M, chemically known as 3,4-dihydro-3-methyl-6-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2(1h)-quinazolinone but generally known as prinoxodan, which bears US NIH Compound Identifier 5362397. European Medicines Agency schedules Prinoxodan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10048MIG.

UNSPSC 51392803 Prinoxodan, a Commodity code, represents pharmaceutical products and medical supplies that state and local governments procure to support public health and emergency response initiatives. Based on recent solicitation activity, the code encompasses naloxone and drug deactivation systems purchased by counties and community health agencies for opioid overdose response and controlled substance management programs. The issuing bodies soliciting under this code include county health departments and special-purpose public health districts focused on substance abuse mitigation and emergency preparedness.

Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, through its e-Procurement Portal. The contract calls for quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with a two-year initial term and one-year renewal option; vendors must include shipping and delivery costs in their bids and comply with drug-free workplace certification, E-Verify requirements, and standard insurance coverage (workers' compensation, commercial general liability, and professional liability). While the source provides only a single recent opportunity, it demonstrates active procurement of life-safety pharmaceutical and medical device inventory by county public health systems in Florida.